Axoft, a neurotechnology company based in Cambridge, Massachusetts, has announced the close of an oversubscribed $55 million Series A funding round led by C.P. Group Innovation, with participation from Alumni Ventures, the Stanford President’s Venture Fund, Hillhouse Investment, and Gaorong Ventures. The company has now raised more than $60 million in total funding and plans to deploy the capital toward expanding global clinical trials and advancing U.S. regulatory approval for its implantable brain-computer interface (iBCI) platform.
Axoft’s iBCIs are designed to safely decode brain signals and improve prognosis and communication for patients with disorders of consciousness. The funding will also support the construction of a good manufacturing practice (GMP) facility to enable scalable production of its devices.
The company’s platform is built on its proprietary Fleuron™ material, which is significantly softer than traditional implant materials and is engineered to improve long-term biocompatibility and signal stability. Compared to conventional polyimide-based implants, Fleuron is up to 10,000 times softer, provides 8 times greater region access, supports 32 times more sensors per thread, and reduces signal attenuation by more than 60%.
Neurological disorders affect approximately one in three people globally, and Axoft’s technology aims to enable more precise measurement of neural activity, supporting AI-driven biomarker discovery and personalized treatment approaches. High-quality neural data is also seen as a key enabler for future AI system development.
The company has already completed first-in-human clinical trials involving more than 11 patients and has demonstrated the ability to capture stable, high-resolution neural data. Additional milestones include collaborations with Mass General Brigham, a clinical study with The Panama Clinic involving four patients undergoing brain tumor resection, and the commercial launch of Fleuron through a licensing agreement with Stanford University.
“At Axoft, the neural data quality we unlock doesn't just make iBCIs more effective, it opens the door to minimally invasive surgery, allows access to deeper brain regions and enables the next generation of AI-driven real-time decoding. Better neural signals are the foundation everything else is built on,” said Dr. Paul Le Floch, co-founder and CEO of Axoft.
The company is also expanding internationally, including opening a subsidiary in Grenoble, France, and continues to invest in research, manufacturing, and interdisciplinary engineering capabilities.
Click here for the original news story.
